drugset
drugset / Trial / NCT05866926

Study to Investigate the Long-term Safety of FAB122 in Patients With Amyotrophic Lateral Sclerosis

NCT05866926 ↗

Phase 3 Terminated 201 enrolled Ferrer Internacional S.A.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

A multicenter, open-label extension study to investigate the long-term safety of FAB122 in patients with Amyotrophic Lateral Sclerosis

Timeline

Start
2023-03-06
Primary completion
2024-01-09
Completion
2024-02-22

Outcome

Outcome not reported

Stopped: “After the analysis of the main ADORE study it is concluded that there is no clinical benefit for the patients.”

Drugs

EvaluationDrugModalityDoseRoute
Subject FAB122 Unknown 100 mg —

Indications

amyotrophic lateral sclerosis